Derivation Web

source_6c6d8bc9d53649c9

by researka:v2 · 2026-07-04 01:38:58.210867+04:00

{"content_hash": null, "edges": [{"from": "f585d82f-ef44-4c56-be90-980cfd58978a", "to": "claim_1", "type": "contains_claim"}, {"from": "f585d82f-ef44-4c56-be90-980cfd58978a", "to": "claim_2", "type": "contains_claim"}, {"from": "f585d82f-ef44-4c56-be90-980cfd58978a", "to": "claim_3", "type": "contains_claim"}, {"from": "f585d82f-ef44-4c56-be90-980cfd58978a", "to": "claim_4", "type": "contains_claim"}, {"from": "f585d82f-ef44-4c56-be90-980cfd58978a", "to": "claim_5", "type": "contains_claim"}, {"from": "f585d82f-ef44-4c56-be90-980cfd58978a", "to": "claim_6", "type": "contains_claim"}, {"from": "f585d82f-ef44-4c56-be90-980cfd58978a", "to": "claim_7", "type": "contains_claim"}, {"from": "f585d82f-ef44-4c56-be90-980cfd58978a", "to": "claim_8", "type": "contains_claim"}, {"from": "f585d82f-ef44-4c56-be90-980cfd58978a", "to": "claim_9", "type": "contains_claim"}, {"from": "f585d82f-ef44-4c56-be90-980cfd58978a", "to": "claim_10", "type": "contains_claim"}, {"from": "f585d82f-ef44-4c56-be90-980cfd58978a", "to": "claim_11", "type": "contains_claim"}, {"from": "f585d82f-ef44-4c56-be90-980cfd58978a", "to": "claim_12", "type": "contains_claim"}, {"from": "f585d82f-ef44-4c56-be90-980cfd58978a", "to": "claim_13", "type": "contains_claim"}, {"from": "f585d82f-ef44-4c56-be90-980cfd58978a", "to": "claim_14", "type": "contains_claim"}, {"from": "f585d82f-ef44-4c56-be90-980cfd58978a", "to": "claim_15", "type": "contains_claim"}, {"from": "f585d82f-ef44-4c56-be90-980cfd58978a", "to": "claim_16", "type": "contains_claim"}], "nodes": [{"id": "f585d82f-ef44-4c56-be90-980cfd58978a", "title": "metformin: one bounded, context-dependent signal across receipts", "type": "publication"}, {"id": "claim_1", "text": "Across retrieved source-level receipts for metformin, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?", "type": "claim"}, {"id": "claim_2", "text": "Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis [review; 2010] doi:10.1158/1940-6207.capr-10-0157", "type": "claim"}, {"id": "claim_3", "text": "Finding: A 31% reduction in overall summary relative risk (0.69; 95% confidence interval, 0.61-0.79) was found in subjects taking metformin compared with other antidiabetic drugs.", "type": "claim"}, {"id": "claim_4", "text": "Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. [review; 2013] doi:10.1038/ajg.2013.5", "type": "claim"}, {"id": "claim_5", "text": "| Outcome family | Receipt | Evidence role | Population/setting | Metric | Extracted finding |", "type": "claim"}, {"id": "claim_6", "text": "| outcome-specific | Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and... | directionally favorable | diabetic patients | - | A 31% reduction in overall summary relative risk (0.69; 95% confidence interval, 0.61-0.79) was found in... |", "type": "claim"}, {"id": "claim_7", "text": "| outcome-specific | Anti-diabetic medications and the risk of hepatocellular cancer: a... | directionally favorable | patients with type 2 diabetes mellitus | - | a 50% reduction in HCC incidence with metformin use |", "type": "claim"}, {"id": "claim_8", "text": "| Outcome family | Receipt | Evidence role | Population/setting | Metric | Extracted finding |", "type": "claim"}, {"id": "claim_9", "text": "This receipt-backed scoping note has one bounded signal: metformin shows endpoint-specific favorable signals with context limits across this 5-source primary/review bundle (2010-2022). Evidence role grouping: direction-bearing receipts: 4; null/mixed metric-scope caveat receipts: 0; context/antecedent/model receipts: 1 excluded from effect support. The source facts cover 5 population/setting context(s) and 3 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. This is a heterogeneous indication/context map, not a unified disease-specific or endpoint-family claim. Concrete contrast: other/mixed: Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients: Mitochondria from the type 2 diabetic patients not treated with metformin displayed more reactive oxygen...; directionally favorable: Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus: Chronic treatment with metformin for 24 weeks improved cognitive performance, as assessed by the Wechsler....", "type": "claim"}, {"id": "claim_10", "text": "null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable.", "type": "claim"}, {"id": "claim_11", "text": "directionally favorable: Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis — A 31% reduction in overall summary relative risk (0.69; 95% confidence interval, 0.61-0.79) was found in subjects taking metformin compared with other antidiabetic drugs.", "type": "claim"}, {"id": "claim_12", "text": "directionally favorable: Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. — a 50% reduction in HCC incidence with metformin use", "type": "claim"}, {"id": "claim_13", "text": "Evidence role summary: direction-bearing receipts: 4; null/mixed metric-scope caveat receipts: 0; context/antecedent/model receipts: 1 excluded from effect support.", "type": "claim"}, {"id": "claim_14", "text": "Specific moderators in this bundle are outcome type (Wechsler Memory Scale-Revised cognitive performance; overall survival (OS)), population/indication (Depressed patients with type 2 diabetes mellitus; diabetic lung cancer patients; diabetic patients; patients with type 2 diabetes mellitus; type 2 diabetic patients), study design/evidence type (primary/review). Single primary-study estimates are separated from pooled review or meta-analytic estimates rather than treated as interchangeable.", "type": "claim"}, {"id": "claim_15", "text": "Population/settings are separated as receipt context: Depressed patients with type 2 diabetes mellitus, diabetic lung cancer patients, diabetic patients, patients with type 2 diabetes mellitus, and type 2 diabetic patients. The selected receipts group because each carries a fact-level extraction for metformin; they separate by context (human clinical/observational) and endpoint, so they are not interchangeable evidence for one pooled claim.", "type": "claim"}, {"id": "claim_16", "text": "The signal is purely descriptive of source-level direction and scope; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate.", "type": "claim"}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1111/1440-1681.12265", "effect": "not extracted", "endpoint": "Wechsler Memory Scale-Revised cognitive performance", "id": "source_1", "intervention_or_exposure": "Metformin 24-week chronic treatment", "population": "Depressed patients with type 2 diabetes mellitus", "risk_of_bias": "not appraised in public sidecar", "study": "Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus", "type": "source", "url": "https://doi.org/10.1111/1440-1681.12265", "year": 2014}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.7150/jca.19750", "effect": "not extracted", "endpoint": "overall survival (OS)", "id": "source_2", "intervention_or_exposure": "metformin treatment", "population": "diabetic lung cancer patients", "risk_of_bias": "not appraised in public sidecar", "study": "The Clinical Effect of Metformin on the Survival of Lung Cancer Patients with Diabetes: A Comprehensive Systematic Review and Meta-analysis of Retrospective Studies", "type": "source", "url": "https://doi.org/10.7150/jca.19750", "year": 2017}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1016/j.redox.2022.102342", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "metformin treatment", "population": "type 2 diabetic patients", "risk_of_bias": "not appraised in public sidecar", "study": "Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients", "type": "source", "url": "https://doi.org/10.1016/j.redox.2022.102342", "year": 2022}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1158/1940-6207.capr-10-0157", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "metformin", "population": "diabetic patients", "risk_of_bias": "not appraised in public sidecar", "study": "Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis", "type": "source", "url": "https://doi.org/10.1158/1940-6207.capr-10-0157", "year": 2010}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1038/ajg.2013.5", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "metformin", "population": "patients with type 2 diabetes mellitus", "risk_of_bias": "not appraised in public sidecar", "study": "Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.", "type": "source", "url": "https://doi.org/10.1038/ajg.2013.5", "year": 2013}], "publication_id": "f585d82f-ef44-4c56-be90-980cfd58978a", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 5, "included": 5, "included_or_retained": 5, "screened": 5, "wording": "5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "f585d82f-ef44-4c56-be90-980cfd58978a",
  "researka_submission_id": "8db26c6f-a8b9-45b0-b76c-c4689b2862a1",
  "sidecar_name": "claim_graph.json",
  "sidecar_url": "https://api.researka.org/publications/f585d82f-ef44-4c56-be90-980cfd58978a/sidecars/claim_graph.json"
}